

Rutgers iJOBS Site Visit to Celgene

June 14, 2016

Agenda

3:00 – 3:30pm – Tom Brieva, Dir, New Product Platforms – Celgene/CCT Overview

3:30 – 4:00pm – Greg Russotti – VP, Technical Operations – Tech Ops Overview

4:00 – 4:30pm – Greg Russotti – GMP Facility tour

4:30 – 5:00pm – Brian Murphy - Dir, Bioprocess Development – Process Development Overview

Thomas A. Brieva, Ph.D.
Director, New Product Platforms
Celgene Cellular Therapeutics
tbrieva@celgene.com



Tom Brieva has played a process development role in the commercialization of cell-based pharmaceuticals at Celgene Cellular Therapeutics since 2004. This role has included the development of robust, reproducible, economically viable cell manufacturing processes and the implementation of them to produce clinical grade product. Tom has led process development for a variety of autologous and expanded allogeneic cell-based products that originated from either within Celgene or from external partners. His work has focused on applying scientific and engineering approaches to achieve pragmatic solutions to manufacturing challenges with a commercial view. Tom received a B.S. in Chemical Engineering and a B.A. in Biological Sciences from Rutgers University. His Ph.D., also from Rutgers, combined Chemical Engineering and Cell and Developmental Biology in an Interdisciplinary Ph.D. program.

Brian Murphy, PhD
Director of Bioprocess Development
Celgene Cellular Therapeutics
bmurphy@celgene.com



Brian Murphy is currently Director of Bioprocess Development at Celgene Cellular Therapeutics in Warren, NJ. His group is responsible for developing, optimizing, and scaling up cell isolation, expansion, and formulation processes and for transferring these technologies to clinical and commercial GMP manufacturing facilities. Prior to joining Celgene in 2007, he worked in the Merck Manufacturing

Division and provided engineering support for the plant start-up of the Biotechnology Manufacturing Center and for the manufacture of a recombinant vaccine. Upon returning to graduate school, he conducted thesis research on gene repair of mouse embryonic stem cells using single-stranded oligonucleotides. With great appreciation for both scientific research and commercial practicality, Brian is currently focused on the challenge of developing novel therapeutics and processes into commercial products.

Brian holds a B.S. in Chemical Engineering from Cornell University, and a M.S./Ph.D. in Chemical and Biomolecular Engineering from the University of Pennsylvania.

Greg Russotti, PhD
VP of Technical Operations
Celgene Cellular Therapeutics
grussotti@celgene.com



Gregory Russotti is currently Vice President of Technical Operations at Celgene Cellular Therapeutics in Warren, NJ, responsible for process development, analytical method development, clinical manufacturing, quality control and quality operations.

Prior to joining Celgene in 2006, Greg spent nearly 15 years at Merck Research Laboratories developing products that included live virus vaccines, monoclonal antibodies, recombinant vaccines, and microbially-produced natural products. He worked on development, scale-up, and tech transfer of cell culture, microbial fermentation, and downstream isolation processes to clinical and commercial manufacturing facilities. Greg received his B.S. and M.S. degrees in Chemical Engineering from Rensselaer Polytechnic Institute and his Ph.D. in Chemical and Biochemical Engineering from Rutgers University.